Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Diabetic Retinopathy Linked to Glycemic Variability in Type 2-Diabetes

By LabMedica International staff writers
Posted on 13 Dec 2018
Latent autoimmune diabetes in adults (LADA) refers to adult diabetes patients who are initially non‐insulin requiring, but have type 1 diabetes mellitus‐associated autoantibodies and who often progress to insulin dependency.

LADA manifests as a wide spectrum of heterogeneous clinical and metabolic phenotypes that are midway between those of classic type 1 diabetes mellitus and type 2 diabetes mellitus. More...
It is estimated that LADA accounts for 4% to14% of patients with a diagnosis of type 2 diabetes mellitus.

Scientists affiliated with the Shanghai Jiao Tong University (Shanghai Shi, China) conducted a cross-sectional analysis of 192 adults (mean age, 56.4 years; 47.9% women; mean BMI, 23.2 kg/m2) with LADA and 2,927 adults with type 2 diabetes (mean age, 57.7 years, 57.3% women, mean BMI, 25.1 kg/m2). The participants were consecutively enrolled in the first group and randomly chosen for the second. All participants were recruited from July 2005 to December 2015. All participants were continuously monitored for 72 hours with a retrospective CGM system (Medtronic Inc, Northridge, CA, USA). Fundus photography was then used to confirm diabetic retinopathy (DR).

The investigators found that found that diabetic retinopathy was more common among those with type 2 diabetes than in those with LADA (26.4% versus 20.3%). Diabetic retinopathy was significantly linked to age, diabetes duration, systolic blood pressure, HbA1c and measurements of glycemic variability in participants with type 2 diabetes based on univariate logistic regression. In participants with LADA, diabetes duration, systolic BP and diastolic BP were the lone risk factors for diabetic retinopathy. They also noted that, overall, participants with LADA weighed less, had better BP and lipid profiles as well as higher glycemic variability and lower fasting C-peptide than those with type 2 diabetes.

The authors concluded that their study provided evidence that intraday glycemic variability (GV), as assessed by continuous glucose monitoring (CGM), was associated with the presence of DR in type 2 diabetes mellitus patients, but not in LADA patients, suggesting that GV should be minimized to decrease the risk of DR in type 2 diabetes mellitus, whereas achieving an optimal HbA1c without increasing the risk of hypoglycemia might be the primary goal in the treatment of LADA. The study was first published on October 10, 2018, in the Journal of Diabetes Investigation.


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.